Trial Profile
A phase III, randomized, double-blind, multi-center, placebo-controlled, parallel-group, safety and efficacy study of SPD465 in adults with attention-deficit hyperactivity disorder (ADHD)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 14 Jul 2021
Price :
$35
*
At a glance
- Drugs Mixed amfetamine salts (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Registrational; Therapeutic Use
- Sponsors Shire
- 30 Sep 2006 New trial record.